JPWO2022099100A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022099100A5 JPWO2022099100A5 JP2023528001A JP2023528001A JPWO2022099100A5 JP WO2022099100 A5 JPWO2022099100 A5 JP WO2022099100A5 JP 2023528001 A JP2023528001 A JP 2023528001A JP 2023528001 A JP2023528001 A JP 2023528001A JP WO2022099100 A5 JPWO2022099100 A5 JP WO2022099100A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- optionally
- lymphoma
- disorder
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 115
- 108091008874 T cell receptors Proteins 0.000 claims 92
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 87
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 64
- 208000035475 disorder Diseases 0.000 claims 64
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims 47
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims 43
- 206010067959 refractory cytopenia with multilineage dysplasia Diseases 0.000 claims 43
- 102000014914 Carrier Proteins Human genes 0.000 claims 38
- 108091008324 binding proteins Proteins 0.000 claims 38
- 101001081189 Homo sapiens Rho GTPase-activating protein 45 Proteins 0.000 claims 37
- 230000003463 hyperproliferative effect Effects 0.000 claims 36
- 150000007523 nucleic acids Chemical class 0.000 claims 32
- 102100027748 Rho GTPase-activating protein 45 Human genes 0.000 claims 31
- 230000003211 malignant effect Effects 0.000 claims 29
- 108010091373 HA-1 antigen Proteins 0.000 claims 27
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 23
- 108010075704 HLA-A Antigens Proteins 0.000 claims 23
- 231100000433 cytotoxic Toxicity 0.000 claims 20
- 230000001472 cytotoxic effect Effects 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 18
- 206010025323 Lymphomas Diseases 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 108090000695 Cytokines Proteins 0.000 claims 15
- 102000004127 Cytokines Human genes 0.000 claims 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 208000032839 leukemia Diseases 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 206010066476 Haematological malignancy Diseases 0.000 claims 13
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 13
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 12
- 208000009527 Refractory anemia Diseases 0.000 claims 12
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 12
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 10
- 239000012636 effector Substances 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 10
- 108700028369 Alleles Proteins 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 8
- 208000032467 Aplastic anaemia Diseases 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 8
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 8
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 8
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 8
- 208000017604 Hodgkin disease Diseases 0.000 claims 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 8
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 208000014951 hematologic disease Diseases 0.000 claims 8
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 8
- 210000004698 lymphocyte Anatomy 0.000 claims 8
- 208000022769 mixed phenotype acute leukemia Diseases 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 7
- 230000004043 responsiveness Effects 0.000 claims 7
- 238000002965 ELISA Methods 0.000 claims 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 6
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 230000006052 T cell proliferation Effects 0.000 claims 6
- 241000703392 Tribec virus Species 0.000 claims 6
- 210000004443 dendritic cell Anatomy 0.000 claims 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 6
- 230000006870 function Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims 6
- 238000003127 radioimmunoassay Methods 0.000 claims 6
- 241000288906 Primates Species 0.000 claims 5
- 241000283984 Rodentia Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000010171 animal model Methods 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims 4
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 4
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims 4
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 4
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 4
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims 4
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims 4
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims 4
- 206010058314 Dysplasia Diseases 0.000 claims 4
- 201000004939 Fanconi anemia Diseases 0.000 claims 4
- 102000001398 Granzyme Human genes 0.000 claims 4
- 108060005986 Granzyme Proteins 0.000 claims 4
- 102210042925 HLA-A*02:01 Human genes 0.000 claims 4
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 claims 4
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 4
- 201000003791 MALT lymphoma Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 4
- 201000007142 Omenn syndrome Diseases 0.000 claims 4
- 206010033661 Pancytopenia Diseases 0.000 claims 4
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 4
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 4
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 4
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 4
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 claims 4
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 claims 4
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 claims 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 230000006044 T cell activation Effects 0.000 claims 4
- 208000002903 Thalassemia Diseases 0.000 claims 4
- 208000005485 Thrombocytosis Diseases 0.000 claims 4
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims 4
- 206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 208000014905 bone marrow failure syndrome Diseases 0.000 claims 4
- 230000002759 chromosomal effect Effects 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 208000003053 chromosome 5q deletion syndrome Diseases 0.000 claims 4
- 208000016532 chronic granulomatous disease Diseases 0.000 claims 4
- 208000024389 cytopenia Diseases 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 4
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 4
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000004235 neutropenia Diseases 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 4
- 208000019465 refractory cytopenia of childhood Diseases 0.000 claims 4
- 201000006845 reticulosarcoma Diseases 0.000 claims 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 4
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims 4
- 208000007056 sickle cell anemia Diseases 0.000 claims 4
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 206010043554 thrombocytopenia Diseases 0.000 claims 4
- 108700026220 vif Genes Proteins 0.000 claims 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 3
- 101001137513 Homo sapiens Outer dynein arm-docking complex subunit 1 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100035708 Outer dynein arm-docking complex subunit 1 Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000003013 cytotoxicity Effects 0.000 claims 3
- 231100000135 cytotoxicity Toxicity 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 238000001262 western blot Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 108010091268 alpha-Macroglobulins Proteins 0.000 claims 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 2
- 102000028861 calmodulin binding Human genes 0.000 claims 2
- 108091000084 calmodulin binding Proteins 0.000 claims 2
- 230000022534 cell killing Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 210000003515 double negative t cell Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 238000011469 lymphodepleting chemotherapy Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229930192851 perforin Natural products 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 210000004986 primary T-cell Anatomy 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000001494 anti-thymocyte effect Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110851P | 2020-11-06 | 2020-11-06 | |
| US63/110,851 | 2020-11-06 | ||
| US202063111462P | 2020-11-09 | 2020-11-09 | |
| US63/111,462 | 2020-11-09 | ||
| US202063129804P | 2020-12-23 | 2020-12-23 | |
| US63/129,804 | 2020-12-23 | ||
| US202163175350P | 2021-04-15 | 2021-04-15 | |
| US63/175,350 | 2021-04-15 | ||
| PCT/US2021/058382 WO2022099100A2 (en) | 2020-11-06 | 2021-11-08 | Binding proteins recognizing ha-1 antigen and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549765A JP2023549765A (ja) | 2023-11-29 |
| JP2023549765A5 JP2023549765A5 (https=) | 2024-11-18 |
| JPWO2022099100A5 true JPWO2022099100A5 (https=) | 2024-11-18 |
Family
ID=81458633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528001A Pending JP2023549765A (ja) | 2020-11-06 | 2021-11-08 | Ｈａ－１抗原を認識する結合タンパク質及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230398217A1 (https=) |
| EP (1) | EP4240490A4 (https=) |
| JP (1) | JP2023549765A (https=) |
| KR (1) | KR20230117576A (https=) |
| AU (3) | AU2021323388C1 (https=) |
| CA (1) | CA3197255A1 (https=) |
| IL (1) | IL302616A (https=) |
| MX (1) | MX2023005179A (https=) |
| TW (1) | TW202227499A (https=) |
| WO (1) | WO2022099100A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4633671A1 (en) * | 2022-12-14 | 2025-10-22 | Yale University | Compositions and methods of use thereof for the treatment of virally driven cancers |
| AU2025202444A1 (en) * | 2024-04-08 | 2025-10-23 | Tscan Therapeutics, Inc. | Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds |
| AU2025202443A1 (en) * | 2024-04-08 | 2025-10-23 | Tscan Therapeutics, Inc. | Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof |
| WO2025231299A1 (en) * | 2024-05-02 | 2025-11-06 | Fred Hutchinson Cancer Center | Tcr t cell therapy targeting ha-1 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201390011A1 (ru) * | 2010-07-28 | 2013-07-30 | Иммьюнокор Лтд. | Т-клеточные рецепторы |
| CA3035075A1 (en) * | 2016-09-23 | 2018-03-29 | Fred Hutchinson Cancer Research Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
| CN112585162B (zh) * | 2018-08-06 | 2025-01-28 | 基因医疗免疫疗法有限责任公司 | Ha-1特异性t细胞受体及其用途 |
| NL2021789B1 (en) * | 2018-10-10 | 2020-05-14 | Academisch Ziekenhuis Leiden | Binding proteins specific for HA-1H and uses thereof |
-
2021
- 2021-11-08 MX MX2023005179A patent/MX2023005179A/es unknown
- 2021-11-08 IL IL302616A patent/IL302616A/en unknown
- 2021-11-08 US US18/035,373 patent/US20230398217A1/en active Pending
- 2021-11-08 EP EP21890215.3A patent/EP4240490A4/en active Pending
- 2021-11-08 WO PCT/US2021/058382 patent/WO2022099100A2/en not_active Ceased
- 2021-11-08 CA CA3197255A patent/CA3197255A1/en active Pending
- 2021-11-08 AU AU2021323388A patent/AU2021323388C1/en active Active
- 2021-11-08 KR KR1020237018962A patent/KR20230117576A/ko active Pending
- 2021-11-08 JP JP2023528001A patent/JP2023549765A/ja active Pending
- 2021-11-08 TW TW110141526A patent/TW202227499A/zh unknown
-
2022
- 2022-09-29 AU AU2022241563A patent/AU2022241563B2/en active Active
-
2026
- 2026-01-28 AU AU2026200575A patent/AU2026200575A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12448445B2 (en) | Transgene genetic tags and methods of use | |
| US20230203124A1 (en) | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation | |
| US11845803B2 (en) | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders | |
| JP7770188B2 (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| US20200085869A1 (en) | Therapeutic regimens for chimeric antigen receptor therapies | |
| JP2022062040A (ja) | プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置 | |
| US20210213063A1 (en) | Combination therapy with chimeric antigen receptor (car) therapies | |
| AU2015361261B2 (en) | Anti-CD70 chimeric antigen receptors | |
| EP3830112A1 (en) | Improving the efficacy and safety of adoptive cellular therapies | |
| CN107847585B (zh) | 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖 | |
| JP2023534808A (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| CA3144070A1 (en) | T cell receptors recognizing r175h or y220c mutation in p53 | |
| JP2024147697A (ja) | 免疫細胞機能の改善 | |
| EP3683229A1 (en) | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy | |
| JPWO2022099100A5 (https=) | ||
| JPWO2022221478A5 (https=) | ||
| CN121773194A (zh) | 培养γδT细胞的方法 | |
| TWI790162B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| JPWO2023086480A5 (https=) | ||
| US20240360236A1 (en) | Methods for targeted immunotherapy of acute myeloid leukemia (aml) | |
| TW202406569A (zh) | 多重ｔ細胞受體組合物、組合療法及其用途 | |
| EP4491630A1 (en) | T-cell receptor for acute myeloid leukemia (aml) | |
| EP4223782A1 (en) | Novel t cell receptors and immune therapy using the same for the treatment of cancer | |
| TW202602496A (zh) | 抗ｈａ－１及抗ｈａ－２結合蛋白用於治療ａｍｌ、ａｌｌ及ｍｄｓ之用途 | |
| JPWO2022221479A5 (https=) |